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Abstract: Soluble ST2 (sST2) is upregulated in response to myocardial stress and may serve as
biomarker in adults with pulmonary hypertension (PH). This prospective cohort study investigated
sST2 levels and its association with echocardiographic and hemodynamic measures, and adverse
clinical outcomes in adults with PH of different etiologies. sST2 was measured during the diagnostic
right heart catheterization for PH, in adult patients enrolled between May 2012 and October 2016.
PH due to left heart failure was excluded. The association between sST2 and a primary endpoint
composed of death or lung transplantation and a secondary composite endpoint including death, lung
transplantation or heart failure, was investigated using Cox regression with adjustment for NT-proBNP.
In total 104 patients were included (median age was 59 years, 66% woman, 51% pulmonary arterial
hypertension). Median sST2 was 28 [IQR 20–46] ng/mL. Higher sST2 was associated with worse right
ventricular dysfunction and higher mean pulmonary and right atrial pressures. Median follow-up
was 3.3 [IQR 2.3–4.6] years. The primary and secondary endpoint occurred in 33 (31.7%) and 43 (41.3%)
patients, respectively. sST2 was significantly associated with both endpoints (HR per 2-fold higher
value 1.53, 95%CI 1.12–2.07, p = 0.007 and 1.45, 95%CI 1.10–1.90, p = 0.008, respectively). However,
after adjustment for NT-proBNP, both associations did not reach statistical significance. In conclusions,
higher sST2 levels are associated with more severe PH and right ventricular dysfunction and yields
prognostic value in adults with PH, although not independently of NT-proBNP.
Keywords: ST2; pulmonary hypertension; biomarkers
1. Introduction
The soluble form of suppression of tumorigenicity-2 (sST2) is a member of the interleukin-1
receptor family. sST2 is known for its release induced by myocardial strain and stress [1], but also for
its involvement in type 2 immune responses [2]. Over the past years, sST2 has arisen as a promising
biomarker in the heart failure population; sST2 has been investigated extensively in the case of left
ventricular failure and has shown a strong prognostic value for mortality in chronic and acute heart
failure patients [3,4]. Its potential relation with right ventricular dysfunction has been investigated to a
much lesser extent.
Right ventricular dysfunction is one of the major problems in patients with pulmonary
hypertension (PH). Elevated pulmonary arterial pressures caused by an increased pulmonary vascular
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resistance can lead to progressive right ventricular failure over time [5], contributing to a very
poor prognosis in these patients [6,7]. The etiology of PH is diverse and it is thought that various
pathophysiologic pathways play a role in the development of this disease [8]. A previous study showed
that the circulating ligand of sST2, interleukin-33, may play a role in the vascular remodeling of the
pulmonary endothelium in idiopathic pulmonary arterial hypertension (iPAH) [9]. Moreover, levels
of sST2 have been correlated with right ventricular dysfunction in pulmonary arterial hypertension
(PAH) patients [10]. As sST2 may thus reflect both cardiac as well as pulmonary vascular remodeling,
sST2 could be a valuable biomarker to monitor deterioration in patients with PH.
The aim of this study was to assess sST2 levels between different PH etiologies, to investigate
associations between sST2 and hemodynamics and measures of RV dysfunction, and to explore the
prognostic value of sST2 for survival in adults with PH.
2. Methods
2.1. Study Design
This is a prospective observational cohort study. We aimed to enroll all consecutive adult patients
at the day of the diagnostic right heart catheterization for PH between May 2012 and October 2016 in
our center. Diagnosis of PH was defined as a mean pulmonary artery pressure (mPAP) of ≥25 mmHg,
measured by right heart catheterization in accordance with the European Society of Cardiology (ESC)
guidelines [11]. Exclusion criteria were: unconfirmed diagnosis of PH due to incomplete diagnostic
work-up, not treatment-naive, aged <18 years old or not capable of understanding and signing
informed consent. Additionally, patients with PH due to left-heart disease were excluded. The study
protocol conforms to the ethical guidelines of the Declaration of Helsinki and was approved by the
local medical ethical committee. All patients gave written informed consent.
Patients were classified according to the World Health Organization (WHO) classification of PH;
PAH, PH due to lung disease, chronic thromboembolic pulmonary hypertension (CTEPH) and PH
with unclear/multifactorial mechanisms (WHO5). Patients with a mixed clinical picture were grouped
under WHO5. WHO 1 patients (PAH) were further stratified in subgroups according to the WHO
classification [11,12]. More details of the study protocol have been published previously [13].
2.2. Study Procedures
During an inpatient visit, patients underwent physical examination by a cardiologist and
pulmonary physician, 6-minute walking test, 12-lead electrocardiography, echocardiography, venous
blood sampling, cardiac computed tomography, and right heart catheterization, all within the
framework of PH screening. Patient characteristics and vital signs were collected. A Swan-Ganz
catheter was used to obtain invasive hemodynamic measurements during right heart catheterization;
pulmonary arterial pressures, right atrial pressures and capillary wedge pressures were measured.
Fick’s principle or thermodilution was used to measure cardiac output. When indicated, a fluid
challenge was performed to exclude PH due to left heart disease. During follow-up, patient management
was according to discretion of the treating physician based on the ESC guideline [11]. Data were
collected and stored in an online electronic case report form PAHTool (version 4.3.5947.29411, Inovoltus,
Santa Maria da Feira, Portugal).
2.3. Echocardiography and Cardiac Computed Tomography Analysis
Two-dimensional transthoracic echocardiography was performed with a commercially available
ultrasound system (iE33, Philip Medical Systems, Best, The Netherlands). The guideline for
echocardiographic cardiac chamber quantification was used for further imaging analysis [14].
The 4-chamber view and parasternal long axis view were used for analysis. We visually graded
left ventricular systolic function as normal, mildly, moderately or severely impaired. Presence of
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pericardial effusion in one of the available views was scored as; mild (<10 mm), moderate (10–20 mm)
or severe (>20 mm).
Cardiac computed tomography was performed according to routine clinical practice. At the level
of the pulmonary artery bifurcation, we measured both the central pulmonary artery diameter and the
aortic diameter [15].
2.4. Definition and Assessment of Endpoints
The primary composite endpoint was defined as a composite of all-cause mortality or lung
transplantation. The secondary endpoint was composed of all-cause mortality, lung transplantation
or hospitalization due to heart failure requiring additional treatment with diuretics. Protocolled
prospective follow-up visits to the outpatient clinic were scheduled with half yearly intervals. CTEPH
patients who were eligible for balloon pulmonary angioplasty or pulmonary endarterectomy, were
referred to a specialized center. Patients were not censored after the procedure. We retrieved
information from the electronic patient records and the municipal personal records database. Patients
were censored at the end of the follow-up period (1 January 2019) when they did not reach one of
the endpoints.
2.5. Biomarker Assessment
Venous blood sampling was performed during diagnostic right heart catheterization and performed
for study purposes only. Blood samples were transferred to the local clinical chemistry laboratory and
N-terminal pro b-type natriuretic peptide (NT-proBNP) was directly measured in fresh blood samples.
The other serum samples were aliquoted and stored by −80 ◦C until batch analysis was performed.
sST2 was measured in serum with a quantitative sandwich monoclonal enzyme-linked immunosorbent
assay (Presage® ST2 assay, CRITICAL DIAGNOSTICS, San Diego, The United States). sST2 is not
significantly affected by sample free-thaw cycles and is reported to be stable up to 15 freeze-thaw
cycles. The samples used to measure sST2 levels were exposed to a maximum of 2 freeze-thaw cycles
with a median storage time of 3.5 [IQR 2.5–5.0] years. The upper-limit of detection was 170 ng/mL,
sST2 measurements reaching the upper limit of detection were further diluted to extent the upper limit.
In addition to the sST2 measurements in PH patients, sST2 was also measured in a healthy cohort
in order to assess assay reproducibility and to obtain reference values [16]. This healthy cohort included
self-declared healthy volunteers, recruited between January 2014 and December 2014. All volunteers
underwent physical examination, electrocardiography, echocardiography and venous blood sampling
on the same day. sST2 showed a good reproducibility with a coefficient of variation of 7.75% and limits
of agreement of −5.59–7.61 ng/mL. This data has previously been published [17]. sST2 measurements
were performed twice in each healthy study participant and once in study patients.
2.6. Statistical Analysis
Continuous variables are presented as mean (SD) or median (inter quartile range (IQR), depending
on the distribution of the data. sST2 and NT-proBNP were 2log transformed because of a skewed
distribution. Comparison of sST2 levels across PH subgroups were performed using the Kruskal–Wallis
test. Pearson or Spearman correlation coefficient was obtained to describe correlations between sST2
and baseline characteristics. Correlations were visualized using scatterplots. Patients were grouped
based on the tertile distribution of sST2 and according to a normal or elevated sST2. Cumulative
endpoint-free survival estimates were derived using the Kaplan–Meier estimator and survival between
groups was compared with the log-rank test for trend. Univariable and multivariable Cox-proportional
hazard regression was used to assess associations between sST2 and study endpoints. We adjusted
for sex and age, and NT-proBNP in separate multivariable analyses. For sST2 sex specific reference
values were used based on 97.5th percentile in the healthy volunteer cohort; >44.50 ng/mL for women
and >55.85 ng/mL for men. Statistical analyses were performed using IBM SPSS Statistics (version 24).
A 2-sided p-value < 0.05 was considered statistically significant.
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3. Results
3.1. Baseline Characteristics
Of the 106 patients who were originally included in this cohort of adults with PH, sST2 was
measured in 104 patients. The patient selection process is shown in Supplemental File 1. The median
age was 59 (IQR 47–69) years, 64% were women and 54% were in New York Heart Association (NYHA)
class III or IV. The cohort consisted of the following PH diagnoses: 53 (51%) PAH, 15 (14%) PH-lung
disease, 21 (20%) CTEPH and 16 (15%) WHO5/multifactorial. (Table 1).
Median sST2 level was 27.9 (IQR 19.6–44.9) ng/mL. sST2 levels according to the different subgroups
of PH are shown in Figure 1. sST2 levels differed significantly between PH subgroups and were the
lowest in CTEPH patients. An elevated level of sST2 was found in 14 women (21%) and in 7 men (18%).
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Figure 1. sST2 levels according to the different PH subclasses and sST2 levels in healthy volunteers. 
Legend: Median sST2 level in each group is indicated by the horizontal line. Y-axis is on the 2log scale. 
Abbreviations: iPAH = idiopathic pulmonary arterial hypertension, PAH-CTD = pulmonary arterial 
hypertension due to connective tissue disease, PAH-CHD = pulmonary arterial hypertension due to 
congenital heart disease, CTEPH = chronic thromboembolic pulmonary hypertension, WHO 5 = 
Pulmonary hypertension classified in group 5, PH due to multifactorial mechanisms. 
3.2. Correlations between sST2 and Clinical Characteristics 
Higher levels of sST2 weakly correlated with a higher NYHA class and shorter 6-minute walking 
distance. Both right ventricular as well as left ventricular measurements on echocardiography 
correlated with sST2. Regarding invasive hemodynamic measurements, sST2 showed a positive 
correlation with the mPAP, mean right atrial pressure and pulmonary vascular resistance. Moreover, 
higher sST2 was associated with lower cardiac output. (Table 2 and Figure 2) As shown in 
supplementary File 2, there was a moderate positive correlation between sST2 and NT-proBNP levels 
(r = 0.54, p = 0.001).   
Table 2. Correlations between sST2 and baseline characteristics. 
 sST2  
 r p-Value 
Clinical characteristics   
Age −0.09 0.346 
Sex 0.11 0.260 
Body mass index −0.15 0.124 
Heart rate 0.28 0.005 
Systolic blood pressure −0.21 0.036 
Oxygen saturation < 90% 0.08 0.417 
NYHA class 3/4 0.23 0.018 
6-minute walking distance −0.29 0.007 
Figure 1. sST2 levels according to the different PH subclasses and sST2 levels in healthy volunteers.
Legend: Median sST2 level in each group is indicated by the horizontal line. Y-axis is on the 2log
scale. Abbreviations: iPAH = idiopathic pulmonary arterial hypertension, PAH-CTD = pulmonary
arterial hypertension due to connective tissue disease, PAH-CHD = pulmonary arterial hypertension
due to congenital heart disease, CTEPH = chronic thromboembolic pulmonary hypertension,
WHO 5 = Pulmonary hypertension classified in group 5, PH due to multifactorial mechanisms.
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Table 1. Baseline characteristics for all patients and stratified according to subgroups of pulmonary hypertension (pH).
Complete Cases (n, %) All PAH PH Lung Disease CTEPH WHO 5/mixed
n = 104 n = 53 n = 15 n = 21 n = 15
Clinical characteristics
Age, years 104 (100) 59 (47–69) 55 (41–66) 64 (55–72) 59 (42–73) 65 (57–70)
Sex, women n (%) 104 (100) 66 (64) 35 (66) 8 (53) 12 (57) 11 (73)
Body mass index, kg/m2 104 (100) 28.1 ± 6.6 26.3 ± 5.8 30.5 ± 6.3 31.4 ± 5.7 27.8 ± 8.5
Heart rate, beats/minute 104 (100) 80 ± 16 80 ± 16 81 ± 12 75 ± 17 85 ± 19
Systolic blood pressure, mmHg 104 (100) 127 ± 18 122 ± 15 125 ± 17 131 ± 13 133 ± 27
Oxygen saturation <90%, n (%) 104 (100) 3 (3) 2 (4) 1 (7) 0 (0) 0 (0)
NYHA class 3/4, n (%) 104 (100) 56 (54) 31 (59) 8 (53) 9 (43) 8 (53)
6-minute walking distance 89 (86) 337 ± 139 348 ± 147 309 ± 115 385 ± 130 261 ± 122
Electrocardiogram
Sinus rhythm, n(%) 102 (97) 90 (87) 46 (87) 13 (87) 18 (86) 13 (87)
QRS duration, ms 100 (96) 98 (90–106) 100 (89–124) 100 (91–111) 94 (88–99) 100 (89–124)
Echocardiogram
RA area, cm2 79 (76) 27.5 ± 26.2 28.0 ± 6.9 28.4 ± 8.4 24.6 ± 10.0 28.2 ± 13.1
RV end diastolic basal dimension, mm 74 (71) 51.5 ± 9.6 52.7 ± 8.1 47.8 ± 4.7 51.1 ± 12.1 50.2 ± 13.0
RV fractional area change, % 72 (69) 28.9 ± 8.6 26.7 ± 7.8 31.3 ± 6.2 33.0 ± 4.3 30.7 ± 12.7
TAPSE, mm 72 (69) 20 ± 5 19 ± 5 19 ± 3 21 ± 3 21 ± 7
LV function, n (%): 99 (94)
Normal 65 (66) 32 (63) 10 (71) 15 (83) 8 (53)
Mildly impaired 29 (30) 17 (33) 4 (29) 3 (17) 5 (33)
Moderately/ severely impaired 4 (4) 2 (4) 0 (0) 0 (0) 2 (14)
LV end diastolic dimension, mm 80 (77) 43.2 ± 7.4 46.7 ± 5.6 46.1 ± 7.3 45.5 ± 5.6 46.8 ± 8.4
Hemodynamics
mPAP, mmHg 104 (100) 42 (35–52) 46 (39–60) 37 (32–41) 37 (30–48) 42 (34–47)
mRAP, mmHg 104 (100) 10 ± 5 11 ± 6 8 ± 4 8 ± 5 11 ± 6
Capillary wedge pressure, mmHg 90 (87) 13 ± 6 11 ± 5 13 ± 4 14 ± 3 19 ± 9
Pulmonary vascular resistance, WU 86 (83) 5.5 (3.4–9.4) 7.9 (5.4–12.0) 4.4 (4.1–5.5) 3.4 (3.0–5.3) 4.1 (2.2–6.8)
Cardiac output, L/min 99 (87) 4.9 (4.0–6.2) 5.0 (3.9–5.8) 5.0 (3.9–5.8) 5.4 (4.9–6.3) 4.9 (4.0–6.8)
Computed tomography
PA diameter, mm 98 (94) 34.4 ± 5.4 35.3 ± 6.0 34.9 ± 4.1 34.4 ± 5.1 31.1 ± 3.3
PA/AO ratio 98 (94) 1.12 ± 0.24 1.20 ± 0.26 1.03 ± 0.12 1.12 ± 0.24 0.98 ± 0.13
Laboratory
sST2, ng/mL 104 (100) 27.9 (19.6–44.9) 34.2 (24.1–54.1) 27.3 (19.2–36.3) 20.2 (15.5–28.6) 26.2 (18.5–47.1)
NT-proBNP, pmol/L 104 (100) 60 (21–226) 120 (26–280) 60 (23–216) 24 (5–36) 31 (12–282)
Abbreviations: NYHA = New York Heart Association, RA = right atrial. RV = right ventricular, TAPSE = trans annular plain systolic excursion, LV = left ventricular, mPAP = mean
pulmonary artery pressure, mRAP = mean right atrial pressure, PA = pulmonary artery, WU = Wood-units AO = aorta, NT-proBNP = N-terminal pro B-type natriuretic peptide,
sST2 = soluble suppression of tumorigenicity-2.
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3.2. Correlations between sST2 and Clinical Characteristics
Higher levels of sST2 weakly correlated with a higher NYHA class and shorter 6-minute walking
distance. Both right ventricular as well as left ventricular measurements on echocardiography correlated
with sST2. Regarding invasive hemodynamic measurements, sST2 showed a positive correlation with
the mPAP, mean right atrial pressure and pulmonary vascular resistance. Moreover, higher sST2 was
associated with lower cardiac output. (Table 2 and Figure 2) As shown in supplementary File 2, there
was a moderate positive correlation between sST2 and NT-proBNP levels (r = 0.54, p = 0.001).
Table 2. Correlations between sST2 and baseline characteristics.
sST2
Clinical Characteristics r p-Value
Age −0.09 0.346
Sex 0.11 0.260
Body mass index −0.15 0.124
Heart rate 0.28 0.005
Systolic blood pressure −0.21 0.036
Oxygen saturation < 90% 0.08 0.417
NYHA class 3/4 0.23 0.018
6-minute walking distance −0.29 0.007
Electrocardiogram
Loss of sinus rhythm 0.17 0.095
QRS Duration 0.15 0.142
Echocardiogram
Right atrial area 0.13 0.269
RV basal dimension 0.17 0.145
RV fractional area change −0.40 <0.001
TAPSE, mm −0.35 0.002
LV end diastolic dimension −0.23 0.044
Hemodynamics
mPAP 0.40 <0.001
mRAP 0.26 0.008
Capillary wedge pressure −0.11 0.314
Pulmonary vascular resistance 0.42 <0.001
Cardiac output −0.27 0.007
Computed tomography
PA diameter 0.07 0.475
PA/AO ratio 0.08 0.426
Laboratory
NT-proBNP 0.54 <0.001
Abbreviations: sST2 = soluble suppression of tumorigenicity-2, NYHA = New York Heart Association, RV = right
ventricular, TAPSE = tricuspid annular plane systolic excursion, LV = left ventricular, mPAP = mean pulmonary
atrial pressure, mRAP= mean right atrial pressure, PA = pulmonary artery, AO = aorta, NT-proBNP = N-terminal
pro B-type natriuretic peptide.
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= tricuspid annular plane systolic excursion.
3.3. Follow-Up
Follow-up data was complete in all patients. After a median follow-up of 3.3 (IQR 2.3–4.6) years,
the primary endpoint occurred in 33 patients (31.7%) and the secondary endpoint in 43 patients (41.3%).
Considering all endpoints separately, 31 patients died, 4 patients underwent a lung transplantation
and 26 patients were hospitalized for heart failure. Causes of death were end-stage heart failure
(n = 9), sudden death, presumed cardiac (n = 4), euthanasia in patients with end-stage pulmonary and
cardiovascular disease (n = 3), multi organ failure (n = 4), kidney and/or live failure (n = 2), and other
diverse causes (n = 9). Regarding the clinical management of the study patients, PH medication was
initiated in 92% of the PAH patients and in 71% of the CTEPH patients. In addition, five patients (24%)
with CTEPH underwent balloon pulmonary angioplasty and three patients (14%) underwent surgical
pulmonary endarterectomy.
3.4. Associations between ST2 and Clinical Outcomes
Figure 3 shows the event-free survival stratified according to patients with a normal and elevated
sST2. Patients with an elevated sST2 were at higher risk of both the primary and secondary endpoint
(p = 0.004 and p = 0.001, respectively), compared with patients with a normal sST2. Survival according
to the tertile distribution of sST2, showed that patients in the first tertile (sST2 < 23.5 ng/mL) had the
highest event-free survival (Supplementary file 3). Cox-regression showed a significant association
between continuous levels of sST2 and the primary and secondary endpoint, independent of age and
sex. However, the association between sST2 and both endpoints did not remain significant when
adjusted for NT-proBNP (Table 3).
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Figure 3. Event-free survi al according to a r al sST2 or an elevated sST2 level in adults with
pulmonary hypertension. Legend: Elevated sST2 was defined as 44.50 ng/mL for women and
55.85 ng/mL for men, based on the 97.5th sST2 percentile in a healthy volunteer cohort. The percentage
shows the cumulative end-point free survival at 6 years of follow-up. sST2 = soluble suppression
of tumorigenicity-2
Table 3. Associations between sST2 and the primary endpoint (death or lung transplantation) and
secondary endpoint (death, lung transplantation or HF).
Hazard Ratio * (95%CI) p-Value
P imary endpoi t (n = 33)
sST2 (univariable) 1.53 (1.12–2.07) 0.007
Adjusted for:
Age and sex 1.59 (1.17–2.16) 0.003
NT-proBNP 1.13 (0.75–1.69) 0.568
Secondary endpoint (n = 43)
sST2 (univariable) 1.45 (1.10–1.90) 0.008
Adjusted for:
Age and sex 1.50 (1.15–1.95) 0.002
NT-proBNP 1.07 (0.75–1.52) 0.712
* Hazard ratio per 2-fold higher value of sST2. Abbreviations: sST2= suppression of tumorigenicity-2, NT-proBNP=
N-terminal pro B-type natriuretic peptide.
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4. Discussion
This is the largest prospective cohort study investigating the prognostic value of sST2 in adults
with PH of various etiologies. Higher sST2 was associated with a shorter 6-minute walking distance,
higher NYHA functional class, right ventricular dysfunction, higher pulmonary vascular resistance
and higher pulmonary- and cardiac pressures. sST2 was elevated in a substantial number of patients
(20%) and these patients had a significant worse transplant-free survival. Moreover, higher sST2 was
significantly associated with an increased risk for all-cause mortality, lung transplantation or heart
failure; however, sST2 yielded no additive prognostic value beyond NT-proBNP.
4.1. Previous Studies
In 2013 Carlomagno et al. investigated sST2 levels in 25 patients with PAH of different etiologies
and 10 controls and found increased levels of sST2 in PAH patients compared with healthy controls.
Moreover, levels of sST2 were related to right ventricular dysfunction [10]. Median sST2 level in this
study was higher than median sST2 in our study patients with PAH (43.3 ng/mL versus 34.5 ng/mL).
To the extent of our knowledge, only 2 studies investigated the prognostic value of sST2 in PH patients.
Zheng et al. investigated sST2 levels in 40 patients with idiopathic PAH and found a significant
association between sST2 and clinical worsening. These patients were followed for a mean follow-up
duration of 14 months in which 12 patients experienced clinical worsening [18]. Another study found
a significant association between sST2 in 43 patients with various types of PH except due to left heart
disease and found higher levels of sST2 in patients who were hospitalized for heart failure or died
during follow-up [19]. This is in line with our study, which demonstrated a significant association
between sST2 and the transplant-free survival in a large cohort of patients with a longer follow-up
duration, whom were prospectively followed since their initial diagnosis.
4.2. Pathophysiology of sST2 in PH
sST2 is part of the interleukin-33(IL-33)/ST2 ligand interaction, a cardio protective system that
is upregulated in cardiomyocytes and fibroblasts as response to myocardial stress or injury. sST2
is the circulating form of ST2 and acts as decoy receptor, blocking the interleukin-33/ST2 ligand
interaction [20]. Upregulation of sST2 therefore abolishes the cardio protective effects and causes
maladaptive remodeling including myocardial hypertrophy, fibrosis and apoptosis [21].
The exact pathophysiology of PH is currently still not fully elucidated [8]; however, there are 3
processes that play a key role in the development: Vasoconstriction, vascular remodeling and micro
thrombotic events [22]. Cytokines are identified to have a major contribution in the pathogenesis of
PH, of which interleukins are probably the most outspoken cytokines that have been investigated in
relation to PAH [23]. It has been proposed that the IL-33/ST2 ligand interaction may also be involved in
the development of PAH. A previous study demonstrated that in endothelial cells from iPAH patients
a marked loss of nuclear IL-33 is present and that knocking down IL-33 induced and released sST2 [9].
Hence, elevated levels of sST2 in this study may partially originate from processes associated with
pulmonary vascular remodeling instead of exclusively induced by myocardial stress. This might
indicate that the height of sST2 reflects both severity of pulmonary endothelial remodeling as well as
progression of right ventricular dysfunction.
In our study, sST2 was associated with hemodynamic and echocardiographic measurements,
suggesting that patients with more severe PH have more ongoing myocardial and endothelial cell
damage reflected by a higher release of sST2. Unfortunately, with data on patient-level we are only
able to speculate about the mechanisms potentially inducing sST2 secretion. Further research is needed
to elucidate the pathophysiologic involvement of sST2 in PH.
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4.3. sST2 and Etiologic Differences of PH
sST2 levels in all subgroups were higher compared to sST2 levels measured in the healthy
volunteers, except for patients with CTEPH in whom sST2 levels seemed similar to levels in healthy
volunteers. Like PAH, it has been investigated that cytokines also play a role in the pathophysiology
of CTEPH [24]. An explanation for the lower sST2 levels in CTEPH patients in our study, could be
presence of less severely PH, expressed by the lower pulmonary vascular resistance seen in these
patients. However, the median pulmonary artery and right atrial pressure in the patients with CTEPH
was equal to the median pressure in patients with PH due to lung disease. Another explanation could
be the more persevering right ventricular function in these patients, as reflected by a higher fractional
area change and a higher trans annular plain systolic excursion. Therefore, less sST2 may be secreted
due to cardiac stress in these patients.
4.4. Limitations
This study is limited by the fact that it includes patients with PH of different etiologies, introducing
heterogeneity in our study cohort. sST2 levels differed between PH subgroups, therefore it is presumable
that sST2 may yield a different prognostic value in each sub diagnosis of PH. The relatively small
sample size restricted further subgroup analysis. Of note, patients with PH due to left heart diseases
were not included in this study, this should be kept in mind when extrapolating the results to other
studies. Although this is currently the largest cohort that investigated the prognostic value of sST2,
it still consists of a relatively low sample size and therefore yields a limited power for multivariable
statistical analyses. Blood sampling was performed in treatment naïve PH patients. However, in
PAH and CTEPH patients, treatment was initiated after diagnosis of PH, during follow-up of the
study. In this study we lacked the ability to adjust for treatment effect in the association between
sST2 and endpoints. Therefore, the associations found in this study, reflect associations between sST2
and outcomes in adults PH patients whom were treated according to the ESC guideline [11]. Serum
samples of these patients were stored by −80 ◦C until batch analysis took place, this could have affected
serum sST2 levels. However, in our study no association was found between the storage duration and
serum sST2 levels.
4.5. Clinical Perspectives
According to our study, patients with an elevated sST2 level have a worse prognosis than patients
with a normal sST2 level at the time of diagnosis of PH. sST2 could therefore be used for risk stratification
in PH, however the independent prognostic value besides NT-proBNP seems limited, questioning the
additive prognostic value sST2 might have in this perspective. sST2 has a lower biological variability
than NT-proBNP [25], this could be advantageous when measuring a biomarker repeatedly over time.
Our study suggests that high sST2 levels are seen in different PH etiologies at the time of diagnosis,
except for CTEPH patients, in whom sST2 levels seemed similar to the general population. It would
be interesting to investigate the influence of PH treatment on sST2 levels over time, as this may
elucidate whether sST2 could be a biomarker for assessing treatment effectiveness. Serial repeated
measurements of sST2 could also help to investigate secretion of sST2 in anticipation to decompensated
heart failure. This study could not provide evidence whether sST2 secretion is induced by myocardial
stretch, pulmonary vascular remodeling, or other potentially involved processes such as type 2 immune
responses. Future studies are needed to reveal the exact mechanisms of sST2 secretion in relation to PH.
5. Conclusions
Levels of sST2 are higher in adults at the time of diagnosis with pulmonary hypertension compared
to healthy people and differs between PH etiologies. Higher sST2 is associated with a worse exercise
capacity, higher pulmonary and cardiac pressures, and with more severe right ventricular dysfunction.
Moreover, sST2 is significantly associated with the risk of death or lung transplantation. Nevertheless,
J. Clin. Med. 2019, 8, 1517 11 of 12
as sST2 yielded no independent prognostic value besides the conventional biomarker NT-proBNP, the
usefulness of sST2 as prognostic biomarker in adults with pulmonary hypertension seems to be limited.
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